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Here we present a plasmonic nanoledge device with high sensitivity and selectivity used to detect 
protein biomarkers simply by functionalizing the device, which specifically binds to particular 
biomolecule or biomarkers. We employ this plasmonic nanoledge device for the detection of 
anti-insulin antibodies of type 1 diabetes (T1D) in buffer and human serum at the range of pg 
ml−1 to 100 ng ml−1. The signal transduction is based on the extraordinary optical transmission 
(EOT) through the nanoledge array and the optical spectral changes with the biological binding 
reaction between the surface functionalized insulin with anti-insulin antibody. Control 
experiments indicate little interferences from the human serum background and addition of other 
proteins such as bovine serum albumin (BSA) and epidermal growth factor (EGF) at 20 ng ml−1. 
The high sensitivity, specificity and easy adaptability of the plasmonic device offer new 
opportunities in biosensing and diagnostic applications for T1D. 
 






Biomolecules or biomarkers play an important role in disease diagnosis and treatment [1]. A few 
methods have been demonstrated for biomolecules or biomarker detection, including surface 
enhanced raman spectroscopy (SERS) [2], enzyme-linked immunosorbent assay (ELISA) [3], 
colorimetry [4], and electrochemical assay [5]. There are unmet needs which motivate to 
improve performance in terms of sensitivity, detection limit, turnaround time, sample amount, 
sample preparation requirements, multiplexing (multiple samples at a time), instrumentation, 
compactness, and portability [1]. The use of metal nanostructures in the biosensors has been 
attractive and one of the most promising alternative methods [6]. Noble metal nanostructures 
have the property of surface plasmon resonance (SPR) [7], this property can be utilized to 
improve the sensitivity and selectivity of the currently available methods [8]. 
 
SPR detection methods have been gaining popularity lately because of their ability to handle 
complex samples and to provide label-free optical biosensors with real time detection [8–10]. 
These sensors can handle complex samples such as human serum/blood without tedious 
preparation and pretreatment [11, 12]. SPR makes use of nanostructures and/or nanostructured 
metal films which remove the need for complex detection instrumentation [13]. These abilities of 
SPR make it a good candidate for creating a plasmonic sensor which is easy to use, reliable, 
capable of on-site detection, selective, and sensitive enough to measure low concentration of 
biomolecules or biomarker targets [14–17]. Coupled with microfluidics, SPR detection can be 
used as a handheld device for easy diagnosis and treatment [18]. 
 
SPR can present localized surface plasmon resonance (LSPR) or surface plasmon polariton 
(SPP) [19], which can increase the local field near the metallic surfaces for sensing, optical 
enhancement, and/or energy conversion [20–24]. When the metal structure gets smaller than the 
wavelength of incident light, it gives rise to a phenomenon called LSPR. LSPR is caused by 
electron oscillations (plasmons) at the surface that are 'localized' within the nanostructure [25]. 
Various nanostructures such as nanoparticles, nanorods and other shapes have been studied for 
LSPR generation [25, 26]. LSPR is very sensitive to the refractive index of the surrounding 
medium [21] and this property can be harnessed for biomolecule or biomarker detection. 
Whenever there is a binding between the surface-bound ligands and free biomarkers or 
biomolecules on the plasmonic surface, there will be change in the refractive index (dielectric 
constant) of the surrounding medium. This change in refractive index contributes to a change in 
the resonant frequency of the plasmon and that phenomenon can be used for the detection of 
various biomarkers or biomolecules [27]. Various shapes, like lines, ledges, circles, rings, and 
squares, can be milled on the surface of nanostructured metal films [28]. Metal films with the 
subwavelength nanostructures [29] exhibit a phenomenon called extraordinary optical 
transmission (EOT) [20]; scientists make use of this property while fabricating various detection 
devices. The array of nanostructures milled over the metal surface in periodic fashion transmit 
more light than the bulk at certain wavelengths [30]. Transmission SPR spectroscopy (tSPR) 
based on EOT and LSPR [31, 32] is of interest to many researchers for sensing or detection 
devices. The tSPR can be used by measuring the EOT allowing for high transmission of light. 
The small size of these structures allows for easy incorporation of a light source and detector. 
This easy alignment and sensitivity due to EOT and LSPR allows for advancement in new lab on 
chip technology. This technology does not require any prisms, precision optics, or temperature 
control, further making tSPR-based sensors small, compact, and easy to carry [33] 
 
In this work, detection of anti-insulin antibodies as a biomarker of type 1 diabetes (T1D) was 
chosen as a model system. Anti-insulin antibodies present in the body fight against the body's 
own insulin cells [34] and decrease the amount of insulin in the body which leads to insulin 
deficiency and results in T1D. The World Health Organization projects that the global 
prevalence of diabetes will increase from 217 million cases in 2005 to 366 million by 2030 [35]. 
Along with being a common disease in adults, diabetes is now the second most common 
pediatric disease. T1D is an autoimmune form of diabetes and the rate of T1D in children is 
rising with a 3% annual rate [36, 37]. Known for being a pediatric disease, T1D is now 
diagnosed during adulthood for approximately one quarter of patients [38]. T1D results from 
cellular mediated autoimmune destruction of the insulin producing pancreatic β-cells [39]. 
Patients suffering from T1D, frequently show life threating symptoms like ketoacidosis, and all 
of them require insulin therapy for life. With the commencement or onset of T1D, patients have 
autoantibodies to at least one of the following: islet cell cytoplasm, insulin (insulin 
autoantibodies (IAAs)) [40], the 65-kDa isoform of glutamic acid decarboxylase (GAD65), 
insulinoma-associated antigen 2 (IA-2), and zinc transporter 8 (ZnT8) (these are collectively 
termed islet autoantibodies) [41, 42]. The development of T1D is predicted by islet 
autoantibodies. While both electrochemical and SPR methods have been developed for insulin 
assays [43], there is an unmet need of medical devices for quantification of islet autoantibodies. 
Current diabetes diagnostics tests like ELISA and lateral flow assay are slow and costly, thus 
making this key test less accessible in areas with limited resources. In spite of a need for better 
diagnostics tests, their development has been challenging. It has been demonstrated over the past 
two decades that usual platforms like lateral flow assays and ELISA do not perform up to the 
mark when applied to T1D diagnostics, and thus do not meet the sensitivity and specificity 
required for this medical situation [44, 45]. 
 
 
Figure 1. Illustration of the gold surface functionalization at the gold surfaces of the nanoledge 
array to immobilize human insulins and the model of plasmonic nanoledge device used for 
biomarker or biomolecule detection. 
 
Based on recent advances in plasmonic nanoslit and nanoledge cavities for trapping and 
detection of various biomolecules or biomarkers [46], a plasmonic chip with a nanostructured 
nanoledge array in the metal film on a dam cross a microfluidic channel [46] was developed, as 
shown in figure 1, for the detection of anti-insulin antibodies of T1D. The dam structure crosses 
a micro-channel that offers an advantage of using less sample volume for analysis. The 
nanostructured ledge array fabricated on the dam provides better capture of small 
biomolecules/biomarkers than straight nanoslits as it combines 50 nm of inner slits and 280 nm 
of outer slit. Small biomolecules/biomarkers can be trapped inside the nanoledge slits and hence 
give better sample delivery and detection sensitivity. The fluidic dam was fabricated with 
lithography technique. Self-assembled monolayers (SAMs) were formed on the surface of the 
exposed gold in nanoledge array. This allowed for easy linkage of Human insulin to the gold 
surface. Then anti-insulin antibodies were flowed over the human insulin and monitored by a 
wavelength shift after binding between the anti-insulin antibodies and the human insulin 
platform. This overcomes the major challenges in rapid, sensitive, and specific diagnosis of T1D, 
by allowing successful detection of ultra-low volumes of samples (buffer and human serum) 
containing T1D anti-insulin antibodies. This new platform offers promise to point-of-care 
detection of several isotypes of anti-insulin antibodies without any fluorescence labeling on a 
single chip [47]. 
 
2. Materials and experimental methods 
 
2.1. Materials and reagents 
 
Cystamine, glutaraldehyde, polyethylene glycol (PEG), human insulin and auto-insulin 
antibodies were purchased from Sigma-Aldrich and used without further purification. All other 
solvents and chemicals were purchased from Sigma-Aldrich. LS 1 light source was purchased 
from Ocean Optics. 
 
2.2. Fabrication of nanoledge plasmonic chip 
 
In this study, a lithography technique with focused ion beam (FIB) was developed, as shown in 
figure 2, to fabricate a flow-over fluidic dam with nanoledge structures. A multi-layer resist was 
used to get the side-wall sloped profile in the desired direction. Photomask was designed in Auto 
computer-aided design (Auto CAD) software. Glass substrates (Glove Scientific) were prepared 
by treatment with a piranha acid (3:1 H2SO4:H2O2) solution, rinsing with deionized (DI) water, 
and N2 drying. The substrates were dehydrated on a hot plate for more than 5 min at temperature 
90 °C. SU-8 3050 photoresist (MicroChem) was applied to a clean, dry glass slide. 
Subsequently, the substrate was soft-baked and flood-exposed (no mask) by OAI mask aligner 
(Milpitas, CA, USA) and then hard-baked to develop a structural layer of SU-8. A 100 nm 
SiO2 film was then deposited by physical vapour deposition (PVD75, Kurt Lesker) upon the SU-
8 layer. Subsequently, second layer of NFR 016 D2 negative photoresist (JSR Micro) was 
applied and patterned by standard photolithography technique. NFR 016 D2 was first spin 
applied and soft baked at 90 °C for 150 s on hot plate. Followed by exposure through the 
negative CAD photomask for 9 s by OAI mask aligner with the dose of 100 mJ cm−2. Then the 
post bake was performed at 90 °C for 120 s, and resist was developed using PD523AD for 1 min, 
then rinsed with water, and dried with N2 gun. Using the NFR resist as an etch mask, CF4 and 
O2 gases from a LAM Rainbow 4400 reactive ion etcher (RIE) were used to etch the oxide layer. 
The SU-8 layer was dry etched isotropically, in a controlled manner, with an O2 plasma using 
SiO2 as an etch mask. Etch parameters used were 100 mT pressure, RF power 100 W, bias −152 
V, time 5 mins, CF4 45 sccm and O2 5 sccm flow rate. A small amount (about 3%–5%) of 
SF6 was added to the gas mixture and it improved the surface roughness of the SU-8 layer. 
Regulating the etch chamber pressure, gas mixture, and RF power gave tunability to the slope 
and sidewall profile of the dam structures. Overcut sidewall profiles (slopes <90°) were desired 
and achieved by tuning the RIE's chamber parameters. The sloped profile with less than 90° 
angle can be easily coated uniformly everywhere by PVD. As PVD is a directional deposition 
technique, we need to have an overcut profile for uniform deposition of metal everywhere. The 
sloped profile was then transferred to PVD for deposition of 4 nm Ti + 250 nm Au + 4 nm Ti + 
100 nm SiO2, with the Ti layers serving as adhesion layers. The thicknesses of the film and the 
deposition rate were monitored with a quartz crystal microbalance (QCM) and were further 
checked with a profilometer (KLA Tencor P-10). Nanoledge structures were then milled into the 
devices on top of the dam structures. Fibics software and a Zeiss Auriga Dual beam FIB/SEM 
were used for milling. Arrays of 100 nanoledge with 600 nm spacing periodicity between each 
structure were milled on the dam along with a reference box or burn box which did not have any 
gold film or any nanoledge structure. The 50 nm inner slit was milled using a 50-pA probe while 
the outer 280 nm step was milled using a 140-pA probe. We used 280 nm–50 nm dimensions as 




Figure 2. Fabrication process for the flow-over fluidic dam using a multi-layered resist (MLR) 
method. (A) Spin apply SU-8 photoresist and soft bake, (B) flood expose and bake the SU-8 post 
exposure, (C) deposit 100 nm of SiO2 atop the cross-linked SU-8 structural layer, (D) spin apply 
JSR NFR 016D2 photoresist, (E) expose the JSR NFR photoresist through the photomask with 
design of the flow-over dam, (F) bake and develop the JSR NFR post exposure, (G) dry etch the 
SiO2 layer with a CF4/O2 plasma, (H) dry etch the SU-8 layer with an O2 plasma, (I) deposit 4 
nm Ti, 250 nm Au, 4 nm Ti, and 100 nm SiO2. 
 
2.3. Functionalization of the plasmonic chip 
 
Cystamine and glutaraldehyde chemistry were used to establish the self-assembled monolayer 
(SAM). A chip surface was thoroughly cleaned with an ethanol rinse, O2 plasma clean, ethanol 
rinse, N2 dry, and UV/ozone treatment. The oxygen plasma treatment was done for 5 min at 100 
W in an oxygen plasma cleaner (South Bay Technologies PC-2000 Plasma Cleaner) at 178.6 
mTorr O2 pressure and a −783 volts DC bias. A 5 mm solution of cystamine in 90% ethanol 
solution was used to form a SAM with the reaction catalysis done by a microwave synthesizer. 
The disulfide bond within the cystamine molecule breaks and yields two sulfur-gold bonds at the 
surface of the chip. The substrate was then rinsed with an ethanol solution of 90% concentration 
and then rinsed with DI water in order to remove the unbound molecules. The terminal amine, 
sticking up from the surface, would then be able to bond to an aldehyde on the next reagent, 
glutaraldehyde, forming an imine bond. A 2.5% solution of glutaraldehyde was used to self-
assemble atop of the formed cystamine layer. This provided a terminal aldehyde group to which 
human insulin can bind. A stock solution of 1 mg ml−1 of anti-insulin antibody solution was 
diluted with a buffer and with human serum to yield a working solution of a different 
concentration. This solution was then delivered to the nanostructured plasmonic nanoledge area 
of the chip and allowed to bond for a few minutes. During this time the entire chip was encased 
in a high-humidity environment so that anti-insulin antibody solution would not dry up and 
results in good binding between human insulin and anti-insulin antibodies. Afterwards, the chip 
was rinsed and dried with a N2 stream. Then, the EOT measurements were taken with the 
modified microscopic spectroscopy. 
 
The chips were re-usable. In order to regenerate the clean metallic surface, the adsorbed SAM 
could be removed by subjecting the substrates to oxygen plasma (South Bay Technologies, PC-
2000 Plasma Cleaner) for 5 min at 100 W. The plasma treated substrates were then exposed to 
sonication in acetone, ethanol, then to water [49] and then were cleaned for 20 min by UV/ozone 
exposure [50] using a Bioforce UV/Ozone ProCleaner. It had previously been demonstrated that 
plasma cleaning does not adversely affect the metallic surfaces and does not add roughness to the 
surface [51]. This is in contrast to the roughness and pinholes that can occur by some cleaning 
methods, such as the use of piranha (H2SO4 and H2O2) [52]. 
 
3. Results and discussion 
 
3.1. Fabrication results and optical characterization 
 
SEM images of a typical fabricated plasmonic nanoledge device is shown in figure 3(a). 
Figure 3(b) shows the FIB images with good contrast which clearly shows the inner 50 nm 
nanoslit and outer 280 nm nanoslit. Each nanoledge has 280 nm outer width and 50 nm inner 
width slits with a periodicity of 600 nm. The 50 nm inner slits are to capture more biomolecules 
or biomarkers, thus increasing sensitivity and specificity. 
 
 
Figure 3. (a) SEM image ofnanoledge array with 600 nm of periodicity. (b) Represent the FIB 
images of the nanoledge. 
 
Transmission spectrum measurements of plasmonic nanoledge chip were taken in air to gain the 
resonant peak locations. As shown in the optical transmission spectra in figure 4, the primary 
resonant peak locations are around 630–640 nm and 690–700 nm. Note that the transmission 
spectrum is the transmittance calculated after subtracting dark and reference. For the 
measurement, the light source was placed underneath the substrate and shone directly onto the 
underside of the dam, which contained the nanoledge structures without any modification. For 
nanoledge structures, which behave as 2D metallic nanomaterial, have two plasmon bands: 
longitudinal plasmons band (690–700 nm) and transverse plasmons (630–640 nm) [53]. The 
transverse plasmons are insensitive to size and surrounding medium but longitudinal plasmon 
band changes with the change in dielectric properties, size, shape and, refractive index of the 
surrounding medium [54]. This change of the peak or band with the change in surrounding 
medium is an indicator of sensor response. Here, the peak around 690–700 nm is due to 
longitudinal plasmons band and changes with the change in the refractive index of the 
surrounding medium. The Gans theory explained the absorption spectra of the 2D metallic 
nanomaterials and shows how absorption spectra changes with the surrounding medium [55]. 
 
 
Figure 4. Represents the transmittance curve (smoothed in red color and, unsmoothed in black 
color) of fabricated plasmonic chip without any modification. 
 
3.2. Optical detection of T1D biomarker 
 
The anti-insulin antibody was used as a target in determining the sensitivity of the plasmonic 
nanoledge device fabricated and functionalized with different techniques, as shown in figure S1 
(available online at stacks.iop.org/Nano/31/325503/mmedia), with the goal of determining if the 
device would be perceptive enough to determine the low concentration of anti-insulin antibodies 
in buffer and in human serum (HS). The plasmonic nanoledge device was functionalized with 
human insulin and then different concentrations of anti-insulin antibodies in buffer or human 
serum were flown over the functionalized device, and the optical transmission spectra were 
recorded using modified microscopic spectrometer (figures S2 and S4). Further, the recorded 
spectra were smoothed and fitted with the best fit polynomial function (up to 8th degree) for 
peak position determination. These experiments were performed with a microscopic 
spectrometer since it has a microscope and stage that allows for measurements to be taken only 
from the area of the device with the fabricated dam and nanoledge structures. For our 
transmission spectrum measurements, we used a broadband white light source (LS 1 Light 
source, 400–1100 nm) instead of typical lasers. The LS 1 light source was connected to the 
instrument with a fiber optic cable and light was shining on the back of the sample, allowing 
optical spectrum collection. The light transmittance of a sample at the detection nanoledge arrays 
was obtained by the equation below: 
 





where, slit represents the nanoledge array, ref is a burn box without any metal coating for full 
light transmission and, dark is any area coated with gold without any nanoledge or burn box and 
light is blocked. 
 
To determine the peak wavelength shift in the transmission spectrum, a MATLAB program was 
created to fit the data using a certain order polynomial function to obtain smoothed transmittance 
curves. The transmittance spectra show red shift along with the antibody biomarker 
concentration increase. A linear relationship between the concentration (Logarithm value) and 
wavelength shift was obtained (figure 6) which is typical for an affinity reaction-based sensing 
[56, 57]. Concentrations of 0.1, 1, 10, and 100 ng ml−1 of anti-insulin antibody were used to 
demonstrate the detection capability of the plasmonic nanoledge device. The reaction time for 
each concentration was 15 mins and then the device was rinsed and dried with nitrogen stream. 
Then the three sets of the transmission spectra measured three times (3X3) for each 
concentration in buffer and in human serum, respectively, were recorded. For each concentration 
a total 9 measurements were taken. The results are summarized in tables S1 and S2. 
 
Figures 5(a)–(b) show the normalized transmittance spectra of anti-insulin antibodies taken for 
different concentration in buffer and in human serum. The 100 ng ml−1 shows the maximum shift 
and for 1 pg ml−1 the shift is very small and almost insignificant. The peak shift was obtained by 
averaging the three sets of measurements. Figure 5(c)–(d) show the wavelength shift with respect 
to different concentrations of anti-insulin antibodies in buffer and in human serum, respectively. 
These plots both show high linearity, with correlation coefficient (R2) above 0.97–0.98 for both 
buffer and human serum. The peak shift observed was due to the change in the refractive index at 
the surface of the plasmonic chip with the binding of anti-insulin antibodies. During the surface 
functionalization, the peak shift after each step of plasmonic chip functionalization was also 
recorded as shown in figure S3. In order to examine the background of human serum, human 
serum contains multiple proteins, but without added anti-insulin antibody, was performed and the 
results are shown in figure S5. The minimal plasmon peak shift during this control concludes that 
the specificity of human insulin functionalized plasmonic nanoledge chip is very high. 
 
 
Figure 5. Representation of peak shift for anti-insulin antibody (a) in buffer and (b) in human 
serum; (c) and (d) show correlation of concentration of anti-insulin antibody with respect to 
wavelength peak shift, the straight line shows the linear fit. 
 
3.3. Control experiments 
 
Control experiments were performed to verify the specificity and selectivity of the human insulin 
modified plasmonic nanoledge device. Bovine serum albumin (BSA) and epidermal growth 
factor (EGF) of concentration (20 ng ml−1) were used as a control. The optical peak shift of the 
insulin functionalized devices with flowing of BSA or EGF in the concentration (20 ng ml−1) 
gives 0.1–0.2 nm from three trials (see table S3), indicating minimal non-specific binding of 
BSA and EGF to the human insulin-modified plasmonic nanoledge device. Three sets of 
individually functionalized devices for BSA and EGF binding were measured and the average 
peak shift is shown in figure 6. 
 
 
Figure 6. Measured peak shift for BSA and EGF to test the specificity of the plasmonic 
nanoledge device. 
 
The measured results of the BSA and EGF interference are consistent and effective for the 
bioassay. The minimal non-specific binding of BSA and EGF to the detection devices indicates 
the high specificity of the designed biosensor. These results indicate that the plasmonic 
nanoledge device, along with tailored surface modification with appropriate receptors, can be 
used as biomarker or biomolecule detection with excellent sensitivity and specificity. 
 
According to SPR sensing principle, there is a relationship between the wavelength shift and 
thickness of layer added as shown in equation (1) [46]: 
 
∆𝜆𝜆 = 𝑇𝑇(𝑇𝑇A − 𝑇𝑇B)[1 − exp(−2𝑑𝑑E 𝑠𝑠d⁄ )] (1) 
 
where Δλ is the peak or wavelength shift, mis the refractive index unit (RIU) 
sensitivity, nA and nB are the refractive index of the medium at the plasmonic sensing surfaces in 
nanoledge arrays after and before the biological binding, dE is the effective thickness of the 
added binding layer and, ld is the decay length of surface plasmon mode. The addition of 
different concentrations of analytes into the plasmonic nanoledge device results in different layer 
thickness which changes the dielectric constant of the surrounding medium at the gold surfaces, 
eventually leading to peak shift. There is red shift with the greater concentration of the analytes 
because higher concentration means more binding and more peak shift. The peak shift as a 
function of the concentration obtained in this work is consistent with our previous results from 
both the theoretical simulation and experiments [46]. Advances in this work of using the 
plasmonic nanoledge device in human serum biomarker sensing further demonstrate a few 
advantages over other thin film based SPR devices in terms of sensitivity and specificity. The 
device is SiO2 coated at the top gold surfaces so it allows only in-cavity detection and avoids 
nonspecific binding at other surface [58]. The plasmonic nanoledge device with outer and inner 
width generates more coupled SPR-induced optical transmission and trap small size 
biomolecules or biomarkers to increase sensitivity [46]. This device has the potential application 




A novel plasmonic nanoledge device was fabricated with lithography and FIB technique, which 
has high sensitivity and selectivity. The plasmonic nanoledge device can be reused with simple 
cleaning in a plasma cleaner. The device can be used for biomolecule or biomarker detection by 
surface functionalization of the device accordingly. In this work, human insulin is used to modify 
the nanoledge devices and demonstrated for detection of anti-insulin antibody, a protein 
biomarker of T1D. The optical transmission peak shift was observed with the change in 
concentration of the protein biomarker binding reactions at the insulin functionalized device. The 
shift in peak wavelength is due to change in the refractive index or dielectric constant at the 
surface of the plasmonic nanoledge device. The sensitivity is high as it can detect in picograms 
concentration in buffer and in human serum. The background of human serum and additional 
control experiments using BSA and EGF indicate minimal interferences caused by non-specific 
binding to the insulin functionalized nanoledge arrays. This study offers promise for the 
development of a new planar plasmonic microfluidic LOC device for early and quick diagnosis 
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